Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01434901 · ClinicalTrials.gov registry record · Phase 1
The Effects of Bethanechol on Glucose Homeostasis
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01434901 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 50 participants.
The verdict
NCT01434901, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Xenin-25 and glucose-dependent insulinotropic polypeptide (GIP) are hormones produced in the intestine that are released into the blood immediately after ingestion of a meal. Together, these 2 hormones increase insulin release and reduce blood glucose levels. Xenin-25 works by increasing acetylcholine release in pancreatic islets. This study will determine if a Bethanechol, a drug that is similar to acetylcholine, also increases insulin release and reduces blood glucose levels after ingestion of a mixed meal.
Interventions
- DRUG Placebo
- DRUG Bethanechol (25 mg)
- DRUG Bethanechol (50 mg)
- DRUG Bethanechol (100 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-08-15 |
| Est. Completion | 2014-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01434901
The ClinicalTrials.gov registry entry for NCT01434901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01434901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01434901 about?
NCT01434901 is a clinical study titled "The Effects of Bethanechol on Glucose Homeostasis". Xenin-25 and glucose-dependent insulinotropic polypeptide (GIP) are hormones produced in the intestine that are released into the blood immediately after ingestion of a meal. Together, these 2 hormones increase insulin release and reduce blood glucose levels. Xenin-25 works by increasing acetylcholi...
What is the current status of trial NCT01434901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2011-08-15. Estimated completion is 2014-07-07.
What interventions are being tested in trial NCT01434901?
The interventions under investigation include: Placebo (DRUG), Bethanechol (25 mg) (DRUG), Bethanechol (50 mg) (DRUG), Bethanechol (100 mg) (DRUG).
Who is sponsoring clinical trial NCT01434901?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.